# Rifaximin for the Secondary Prevention of Recurrent Pouchitis

> **NCT06312683** · PHASE4 · RECRUITING · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 16 (estimated)

## Conditions studied

- Pouchitis

## Interventions

- **DRUG:** Rifaximin 550 MG Oral Tablet [XIFAXAN]

## Key facts

- **NCT ID:** NCT06312683
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06312683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06312683, "Rifaximin for the Secondary Prevention of Recurrent Pouchitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06312683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*